Major Price Cut: Making Weight Management Affordable

Emcure Pharmaceuticals has announced a substantial price reduction for its weight management drug, Poviztra. The semaglutide injection's cost will drop by up to 55%, with the new prices effective from April 3, 2026, targeted to make obesity treatments more accessible to Indian patients.

The starting dose, now priced at Rs 3,999 per month with all taxes included, highlights Emcure's commitment to combating the obesity epidemic affecting over 254 million people in India. The company aims to expand access to scientifically validated weight-management therapies at a time when obesity poses a serious public health challenge.

CEO and Managing Director Satish Mehta emphasized the importance of this price revision, aligning it with Emcure's mission of improving health outcomes. This decision follows Novo Nordisk India's recent price adjustments for similar semaglutide-based drugs, Ozempic and Wegovy, and the launch of generic versions in the Indian market.